 |
| |
| Feb-28-20 | Downgrade |
JP Morgan |
Neutral → Underweight |
|
|
| Feb-18-20 | Downgrade |
Wedbush |
Outperform → Neutral |
|
|
| Nov-20-19 | Resumed |
Guggenheim |
Neutral |
|
|
| Oct-01-19 | Downgrade |
Guggenheim |
Buy → Neutral |
|
|
| Jun-03-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| May-29-19 | Initiated |
ROTH Capital |
Neutral |
$10 |
|
| Apr-12-19 | Resumed |
Guggenheim |
Buy |
$24 |
|
| Sep-13-18 | Resumed |
Leerink Partners |
Outperform |
$24 |
|
| Jun-28-18 | Initiated |
Raymond James |
Mkt Perform |
|
|
| Jun-15-18 | Initiated |
JP Morgan |
Neutral |
$19 |
|
| May-18-18 | Initiated |
Wedbush |
Neutral |
|
|
| Nov-06-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$41 → $50 |
|
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Outperform |
$41 |
|
| Mar-02-17 | Initiated |
Instinet |
Buy |
$94 |
|
| Oct-25-16 | Initiated |
Citigroup |
Buy |
|
|
| Jan-21-16 | Initiated |
Credit Suisse |
Outperform |
|
|
| Dec-04-15 | Resumed |
Wells Fargo |
Outperform |
|
|
| Oct-19-15 | Reiterated |
Oppenheimer |
Outperform |
$45 → $48 |
|
| Jul-31-15 | Initiated |
Citigroup |
Buy |
|
|
| May-15-15 | Initiated |
Oppenheimer |
Outperform |
$45 |
|
|
|
| May-29-20 12:38PM | Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +5.79% |
| May-15-20 09:37AM | Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now? Zacks |
| May-10-20 09:55AM | Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St. |
| May-07-20 04:05PM | Five Prime Therapeutics Reports First Quarter 2020 Results Business Wire +11.14% |
| Apr-30-20 04:05PM | Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call Business Wire |
| Apr-22-20 04:05PM | Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format Business Wire |
| Apr-14-20 09:00AM | Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer Business Wire +7.35% |
| Apr-09-20 07:35AM | Here's Why Five Prime Therapeutics (NASDAQ:FPRX) Must Use Its Cash Wisely Simply Wall St. +10.20% |
| Mar-20-20 03:32AM | Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents |
| Mar-13-20 09:25AM | Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology Business Wire |
| Feb-27-20 05:45PM | Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates Zacks -10.56% |
| Feb-25-20 04:22PM | Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire -7.24% |
| Feb-20-20 12:31PM | Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks |
| Feb-19-20 09:25AM | Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs Business Wire +18.33% |
| Feb-18-20 09:25AM | Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer Business Wire |
| Feb-13-20 04:05PM | Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call Business Wire -8.11% |
| Jan-10-20 09:28AM | If You Had Bought Five Prime Therapeutics (NASDAQ:FPRX) Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today Simply Wall St. -6.00% |
| Dec-30-19 01:05PM | Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire |
| Dec-27-19 02:26PM | Longtime biotech exec walks away from board to concentrate on startup American City Business Journals |
| Dec-26-19 04:05PM | Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams From Board of Directors Business Wire |
| Dec-20-19 01:54PM | Head of big South San Francisco biotech thriving in first CEO role American City Business Journals |
| Dec-16-19 06:17PM | Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -5.80% |
| Dec-10-19 11:14AM | Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy ? Insider Monkey +5.14% |
| Nov-09-19 07:00AM | Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting Business Wire |
| Nov-08-19 01:02PM | Insiders Roundup: Crocs, OPKO Health GuruFocus.com |
| Nov-06-19 06:45PM | Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks |
| 04:05PM | Five Prime Therapeutics Reports Third Quarter 2019 Results Business Wire |
| Oct-30-19 10:33AM | Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks |
| Oct-24-19 04:01PM | Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call Business Wire |
| Oct-11-19 04:04PM | Insiders Roundup: Facebook, American Defense Systems GuruFocus.com |
| 08:14AM | The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga |
| Oct-10-19 09:57PM | South San Francisco biotech to cut another 70 jobs, may sublease space American City Business Journals |
| 04:01PM | Five Prime Announces Restructuring Business Wire |
| Oct-02-19 07:30AM | Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism Bloomberg +5.15% |
| Sep-30-19 03:01AM | Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress Business Wire -9.36% |
| Sep-20-19 09:59AM | Peninsula biotech CEO resigns in latest corner office switch American City Business Journals |
| Sep-19-19 04:05PM | Five Prime Therapeutics Announces Management Transition Business Wire |
| 12:18PM | What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock? Simply Wall St. |
| Aug-22-19 07:45PM | Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire |
| Aug-15-19 10:16PM | Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-07-19 06:25PM | Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:05PM | Five Prime Therapeutics Reports Second Quarter 2019 Results Business Wire |
| Aug-01-19 03:06PM | Cancer-fighting Peninsula company postpones $92 million IPO American City Business Journals |
| Jun-25-19 11:56AM | Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Simply Wall St. |
| Jun-24-19 04:05PM | Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors Business Wire |
| 01:28PM | Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy? Insider Monkey |
| Jun-18-19 08:50AM | Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks |
| Jun-09-19 03:05PM | Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors Business Wire |
| 03:00PM | Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire |
| Jun-01-19 09:01AM | Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting Business Wire |
| May-24-19 04:01PM | Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire |
| May-17-19 12:45PM | Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents |
| May-15-19 06:39PM | Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors Business Wire |
| 05:45PM | Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting Business Wire |
| May-09-19 11:23AM | Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript Motley Fool -5.03% |
| May-08-19 06:45PM | Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates Zacks |
| 05:39PM | Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press |
| 04:05PM | Five Prime Therapeutics Reports First Quarter 2019 Results Business Wire |
| May-01-19 10:33AM | Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline Zacks |
| Apr-30-19 09:04AM | Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO? American City Business Journals -7.20% |
| Apr-17-19 07:56PM | Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8 Business Wire |
| 01:27PM | What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory? Simply Wall St. |
| Mar-25-19 09:19AM | Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals |
| Mar-20-19 02:09PM | Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents |
| Mar-19-19 09:28AM | Will Five Prime Therapeutics Continue to Surge Higher? Zacks |
| Mar-11-19 06:00AM | Five Prime Has 5 Drugs in its Pipeline MoneyShow |
| Mar-05-19 06:05PM | Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire |
| Feb-26-19 09:47PM | Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 04:05PM | Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire |
| Feb-20-19 08:05PM | Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150 Business Wire |
| Feb-07-19 04:05PM | Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 Business Wire |
| Feb-04-19 05:05PM | Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum Business Wire |
| Jan-30-19 11:45PM | Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals |
| Jan-28-19 09:37AM | MacroGenics Up on Lifting of Partial Hold on Cancer Candidate Zacks -8.42% |
| Jan-24-19 03:13AM | Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? Zacks |
| Jan-17-19 02:05PM | Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Business Wire +5.98% |
| Jan-16-19 07:40AM | Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Jan-15-19 05:08PM | Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +9.40% |
| 04:05PM | Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities Business Wire |
| Jan-14-19 06:41PM | Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium Business Wire |
| Jan-13-19 03:50PM | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga |
| Dec-12-18 04:05PM | Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire |
| Nov-29-18 04:05PM | Five Prime Therapeutics Announces Changes to its Board of Directors Business Wire |
| Nov-27-18 07:15AM | 3 Top Biotech Stocks to Buy Right Now Motley Fool |
| Nov-20-18 04:05PM | Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire |
| 01:52PM | Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
| Nov-14-18 04:05PM | Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein Business Wire |
| Nov-12-18 10:21AM | Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more American City Business Journals |
| Nov-09-18 08:40AM | New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Nov-06-18 06:15PM | Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks |
| 05:09PM | Five Prime Therapeutics: 3Q Earnings Snapshot Associated Press |
| 04:05PM | Five Prime Therapeutics Announces Third Quarter 2018 Financial Results Business Wire |
| Nov-05-18 10:36AM | Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer Business Wire |
| Nov-01-18 10:23AM | Big pharma leases almost 500,000 square feet for new research center American City Business Journals +7.00% |
| Oct-23-18 04:05PM | Five Prime Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 6 Business Wire |
| Oct-16-18 09:00AM | Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 Business Wire +6.18% |
| Oct-10-18 02:42PM | Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Oct-01-18 08:00AM | Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire |
| Sep-26-18 04:05PM | Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire |
| Sep-10-18 09:00AM | Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire |
|
|
|
|
| Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BVF PARTNERS L P/IL | 10% Owner | May 14 | Buy | 4.10 | 293,587 | 1,203,707 | 4,179,093 | May 18 08:02 PM | | BVF PARTNERS L P/IL | 10% Owner | Dec 20 | Buy | 4.05 | 515,020 | 2,085,831 | 3,929,792 | Dec 26 05:59 PM | | BVF PARTNERS L P/IL | 10% Owner | Dec 09 | Buy | 4.02 | 135,000 | 542,363 | 3,648,474 | Dec 11 06:13 PM | | BERGER FRANKLIN M | Director | Dec 03 | Sale | 4.00 | 47,890 | 191,560 | 5,000 | Dec 04 06:28 PM | | BERGER FRANKLIN M | Director | Dec 02 | Sale | 3.92 | 32,090 | 125,793 | 52,890 | Dec 04 06:28 PM | | BVF PARTNERS L P/IL | 10% Owner | Nov 22 | Buy | 3.40 | 1,120,010 | 3,808,146 | 3,534,600 | Nov 26 05:59 PM | | BVF PARTNERS L P/IL | 10% Owner | Nov 05 | Buy | 4.00 | 968,112 | 3,872,448 | 2,958,503 | Nov 07 07:22 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 31 | Buy | 3.85 | 6,833 | 26,304 | 2,461,782 | Oct 31 06:24 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 30 | Buy | 3.89 | 20,081 | 78,157 | 2,458,366 | Oct 31 06:24 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 29 | Buy | 3.90 | 2,400 | 9,353 | 2,447,977 | Oct 31 06:24 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 25 | Buy | 3.75 | 30,782 | 115,349 | 2,446,950 | Oct 25 05:43 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 24 | Buy | 3.74 | 135,388 | 506,987 | 2,431,222 | Oct 25 05:43 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 23 | Buy | 3.75 | 3,200 | 11,986 | 2,355,186 | Oct 25 05:43 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 08 | Buy | 3.68 | 60,412 | 222,497 | 2,351,986 | Oct 08 05:40 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 07 | Buy | 3.75 | 525,070 | 1,968,664 | 2,320,979 | Oct 08 05:40 PM | | BVF PARTNERS L P/IL | 10% Owner | Oct 04 | Buy | 3.74 | 16,000 | 59,800 | 2,054,006 | Oct 08 05:40 PM | | Knickerbocker Aron Marc | President & CEO | Jun 07 | Option Exercise | 5.54 | 11,357 | 62,918 | 195,828 | Jun 10 01:53 PM |
|
|
|
|
|
|
